Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Valneva initiates Phase 1/2 clinical study of inactivated, adjuvanted COVID-19 vaccine candidate

worldpharmanewsDecember 17, 2020

Tag: Valneva , COVID-19 vaccine , VLA2001 , IXIARO , Encephalitis

PharmaSources Customer Service